Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00184080
Status:
COMPLETED
Last Update Posted:
2014-05-21
First Post:
2005-09-13
Brief Title:
Elsamitrucin SPP 28090 in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma
Sponsor:
University of Southern California
Organization:
University of Southern California
Study Overview
Official Title:
A Multicenter Open-Label Non-Randomized Phase II Study of Elsamitrucin SPP 28090 in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety of an experimental drug called Elsamitrucin in people with non-Hodgkins lymphoma and to see if it can shrink their tumors Elsamitrucin has not been approved by the Food and Drug Administration FDA However the FDA is permitting the use of this drug for this study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None